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Abstract
Background: The vasopressin V2-receptor antagonist tolvaptan is used to treat cirrhotic patients with ascites. We
investigated the outcome of long-term treatment.
Methods: This was a single-center retrospective study. Overall, 170 cirrhotic patients (95 males, median age 63
years) were enrolled and received tolvaptan orally after hospitalization for ascites, which included treatment with
conventional diuretics. We compared patients who withdrew tolvaptan treatment after < 1 year (n = 90) with
patients who continued treatment for ≥1 year (n = 37). In continuously treated patients, the pretreatment and
post-treatment (1 year) blood biochemistry values were assessed.
Results: Overall, 37 patients received treatment for ≥1 year and showed a higher response after tolvaptan therapy.
The reduction in body weight was 2.0 (− 3.4–17.2) kg compared to discontinued cases, which had a body weight
reduction of 1.1 (− 6.2–7.5) kg after 1 week. The group that received treatment for ≥1 year had a significantly lower
rate of the complication gastroesophageal varices and also showed better liver function. In patients with continued
treatment, serum levels of albumin was significantly higher without renal disturbance after 1 year of treatment. The
prothrombin time/international normalized ratio and ammonia level were also significantly improved. Multivariate
analyses showed that a change in body weight reduction and serum levels of albumin were predictive factors of
continued administration.
Conclusions: Long-term tolvaptan treatment increased serum levels of albumin, decreased ammonia levels, and
preserved renal function after 1 year of treatment. A reduction in body weight after 1 week was associated with a
favorable outcome of tolvaptan therapy.
Keywords: Vasopressin V2-receptor antagonist, Tolvaptan, Liver cirrhosis, Body weight reduction, Long-term
outcome
Background
Liver cirrhosis occurs in end-stage liver disease, and as-
cites accumulation is a sign of decompensated liver cir-
rhosis. Following the development of ascites, the 5-year
survival rate is only 50% [1, 2]. After the development of
dilutional hyponatremia, refractory ascites, and type 2
hepatorenal syndrome, the 1-year probability of survival
is 25.6, 31.6, and 38.5%, respectively [2]. Ascites treat-
ment for liver cirrhosis patients is important, and the
vasopressin V2-receptor antagonist tolvaptan has dra-
matically improved this treatment [3, 4]. The Japanese
Society of Gastroenterology recommended the use of
tolvaptan prior to albumin administration or ascites
drainage in 2015 [5]. Arginine vasopressin (AVP) triggers
vasoconstriction by binding to V1a receptors, and pro-
motes water re-absorption in the kidney by binding to
V2 receptors, which are primarily responsible for the
antidiuretic effects of AVP [3]. Tolvaptan selectively
blocks the binding of vasopressin to V2 receptors.
In previous studies, we have shown that treatment
with tolvaptan for 6 months is efficacious and safe and
may improve the prognosis of cirrhotic patients [6, 7].
Median survival is significantly longer in patients with
less ascites accompanying diuretic treatment [8]. Accord-
ing to a meta-analysis of randomized controlled trials, a
tolvaptan-associated reduction in diuretic use is associated
with lower serum sodium levels and maintenance of renal
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function, but no survival benefits were apparent in either
the short- or long-term [9].
Tolvaptan response does not depend on albumin or
sodium levels [3, 10]. These characteristics are beneficial
for cirrhotic patients because cirrhosis results in ex-
tremely low levels of albumin and sodium in end-stage
liver disease [11]. Conventional diuretics, particularly
furosemide, bind reversibly to carrier protein; therefore,
their mechanism of action requires albumin as the car-
rier protein. This leads to a decrease in the action of
diuretics in cirrhosis. In addition, cirrhosis is often com-
plicated by hyponatremia. It is sometimes difficult to
treat using conventional diuretics because reducing or
abolishing sodium chloride reabsorption further reduces
serum levels of sodium, and hyponatremia is also associ-
ated with poor prognosis [12, 13]. Tolvaptan increases
sodium levels and improves survival [13].
However, no studies have investigated long-term tol-
vaptan administration. Here, we investigated whether
long-term tolvaptan treatment may improve liver and
renal function, the predictive factors of long-term treat-
ment, and the characteristics of patients who could stop
treatment after improvement of ascites.
Methods
Patients and study design
This was a single-center, retrospective, observational
study conducted between September 2013 and July
2018. A total of 170 cirrhotic patients (95 males, 56%, 75
females, 44%), complicated with ascites, who received
tolvaptan (Samsca™; Otsuka Pharmaceutical Co. Ltd.,
Tokyo, Japan) after hospitalization with a salt/water-res-
tricted diet (including four retreatment patients) were
enrolled. Tolvaptan was started from a half dose (3.75
mg once per day) and it was increased to 7.5 mg/day if
the response or body weight reduction was insufficient.
Tolvaptan was added on other diuretics including 0–
160 mg/day furosemide and/or 0–400 mg/day spirono-
lactone. Excluded criteria was patients with severe renal
dysfunction (estimated glomerular filtration rate [eGFR]
< 15mL/min/1.73 m2 or serum levels of creatinine > 3.5
mg/dL) and patients with a hepatic coma scale score >
II. Overall, of the patients who were excluded in the
discontinued cases (n = 90), eight patients could stop
treatment and seven continued treatment for < 1 year.
Patients who received tolvaptan treatment for < 1 year
and ≥ 1 year (n = 37) were compared (Fig. 1). Denver
shunts were placed following the manual of the pro-
cedure [14].
This study was conducted according to the principles
of the Declaration of Helsinki and the ethics rules of
Tokyo Women’s Medical University Hospital (TWMU,
Tokyo, Japan). The TWMU Institutional Review Board
approved the study protocol (approval no. 3258-R).
Clinical parameters
The following baseline characteristics of patients were
assessed: age, sex, clinical history, body weight, urine
Fig. 1 Flow chart of the study design. Overall, 170 cases with cirrhosis were treated with tolvaptan. Eight patients finished treatment due to
improved ascites, and treatment was stopped in 90 cases due to poor condition, death, and liver transplantation. By contrast, 37 cases were
continuously administered tolvaptan for ≥1 year
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volume, underlying hepatic diseases, rates of complica-
tions of cirrhosis (i.e., varices, hepatocellular carcinoma,
and hepatic encephalopathy), treatments including the
administration of diuretics and branched-chain amino
acids (BCAA), and procedures including ascites drainage
and implantation of Denver shunts. Blood samples for
biochemistry and hematological data were collected at
the time of administration of tolvaptan and after 1 year
of treatment. Urine volume was determined the next day
and the reduction in body weight was evaluated after 1
week. Laboratory tests included serum concentrations of
albumin, total bilirubin, aspartate aminotransferase,
alanine transaminase, γ-glutamyltransferase, ammonia,
alpha-fetoprotein and des-gamma-carboxy prothrom-
bin, platelet counts, hematocrit, prothrombin time
(PT), and PT/international normalized ratio (INR).
The modified Child-–Pugh (CP) score [15] and the
model for end-stage liver disease (MELD) score [16]
were used to evaluate liver function.
Follow-up and outcomes
The patients were hospitalized and administered tolvap-
tan for 1–2 weeks. After discharge, patients were
followed every 1–2 months at an outpatient clinic to
check biochemical parameters. One year after tolvaptan
administration, outcomes were monitored and evaluated
the efficacy and the condition.
Statistical analyses
Data are presented as medians with minimum and max-
imum values. Significant differences between the two
groups were assessed using the Mann–Whitney U test and
χ2 test with the SPSS statistical software package (SPSS
Inc., Chicago, IL, USA). Pretreatment and post-treatment
values were compared using Wilcoxon signed-rank
tests. Differences were considered statistically signifi-
cant at p < 0.05. Multivariate logistic regression ana-
lyses were performed with the likelihood ratio test to
assess their fit after 1 year of tolvaptan treatment.
Results
Baseline characteristics of patients pretreated with
tolvaptan
A flow chart of our study is shown in Fig. 1. A total of
170 cirrhotic patients were treated with tolvaptan and
64% of patients had their dose increased to 7.5 mg/day.
The median age was 63 (range, 21–90) years old, and 56%
were male (Table 1). Underlying liver diseases included
hepatitis C virus (HCV, 28%), hepatitis B virus (HBV, 7%),
alcoholic liver disease (ALD, 28%), non-alcoholic fatty liver
disease (NAFLD, 11%), and primary biliary cholangitis
(PBC; 10%). Regarding complications of liver cirrhosis, gas-
troesophageal varices (68%), hepatocellular carcinoma
(HCC; 32%), and hepatic encephalopathy (27%) were
observed.
The median urine volume on the next day of treat-
ment was 1595 (120–6630) mL and the body weight
change was − 1.5 (− 17.2 to + 6.2) kg after 1 week of
treatment.
The distribution of diuretic use is shown in Fig. 2. The
majority of cirrhotic patients with ascites who started
tolvaptan treatment were taking 0–50mg/day spirono-
lactone and 20–40 mg/day furosemide.
Patients who could stop treatment due to improved
ascites
Of the patients who withdrew from tolvaptan treatment
after < 1 year, the reasons included death (n = 59), liver
transplantation (n = 22), hemodialysis or non-response
to treatment (n = 9), transfer to another hospital (n = 28),
and improvement (n = 8). Overall, nine patients stopped
tolvaptan treatment (Table 2). Six cases had ALD, and
patients who stopped alcohol consumption were able to
successfully improve their ascites without tolvaptan
treatment. However, two patients required retreatment,
which was accompanied by a return to alcohol con-
sumption. In a patient with methotrexate-related liver
disease, ascites improved after discontinuing methotrex-
ate. A patient with HBV temporarily recovered by
undergoing nucleic acid analog treatment, but required
tolvaptan treatment again.
Comparison of laboratory data between patients who
withdrew and continued tolvaptan treatment
Tolvaptan was introduced to cirrhotic patients with asci-
tes who were also taking conventional diuretics. How-
ever, almost all of the patients could not continue
long-term treatment (Fig. 3). Overall, 62 patients discon-
tinued tolvaptan within 3 months, 30 in 3–6 months,
and 31 in 6 months to 1 year. Only 37 cases were treated
for ≥1 year. The median treatment period was 132 days.
Patients who were treated with tolvaptan for < 1 year (n
= 90, without improved and continued treating cases) were
compared to those treated for ≥1 year (n = 37, Fig. 1, Table
1). Changes in body weight after 1 week were significantly
greater in patients who continued treatment (− 2.0 kg [−
17.2 to + 3.4]; p = 0.03) than in those who discontinued
treatment (− 1.1 kg [− 7.5 to + 6.2]). Consistent with the eti-
ology of liver disease, the rate of ALD increased in such pa-
tients, who also had less gastroesophageal varices. A
Denver shunt was placed in three patients who continued
treatment and in only one patient who discontinued treat-
ment. The rates of other ascites therapies including diuretic
use, administration of BCAA, and CART or drainage of as-
cites were not significantly different between the groups.
The serum levels of albumin (p = 0.03) and sodium (p
= 0.01) were significantly higher, whereas the level of
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Table 1 Baseline characteristics of the patients and laboratory data at initiation of tolvaptan
Total (n = 170) Discontinued* (n = 90) Continued** (n = 37) p-value * vs. **
Age (years) 63 (21–90) 60 (21–85) 63 (22–90) 0.28
Sex (% of males) 95/170 (56%) 47/90 (52%) 23/37 (62%) 0.31
BW (kg) 61.9 (34.4–143.6) 61.6 (37.4–98.9) 62.9 (34.4–143.6) 0.48
BW after 1 week (kg) 60.9 (32.7–136.2) 61.5 (36.3–103.8) 61.0 (32.7–136.2) 0.75
BW reduction after 1 week (kg) 1.5 (−6.2–17.2) 1.1 (−6.2–7.5) 2.0 (−3.4–17.2) 0.03
Urine volume (mL) 1595 (120–6630) 1450 (120–6630) 1690 (195–4460) 0.77
Etiology of liver disease (%) 0.07
HCV 48 (28%) 28 (31%) 6 (16%)
HBV 12 (7%) 4 (4%) 4 (11%)
ALD 48 (28%) 22 (24%) 15 (41%)
NAFLD 19 (11%) 7 (8%) 5 (14%)
PBC 17 (10%) 7 (8%) 4 (11%)
Others 31 (18%) 24 (27%) 4 (11%)
Complication (%)
Gastroesophageal varices 109/160 (68%) 62/82 (76%) 21/37 (57%) 0.04
Hepatocellular carcinoma 54/170 (32%) 26/90 (29%) 13/37 (35%) 0.51
Hepatic encephalopathy 46/170 (27%) 33/90 (37%) 8/37 (22%) 0.10
Diuretics
Furosemide dose (mg/day) 20 (0–160) 20 (0–120) 20 (0–80) 0.48
Spironolactone dose (mg/day) 50 (0–400) 50 (0–400) 50 (0–150) 0.24
Branched-chain amino acid (%) 150/170 (88%) 76/90 (84%) 35/37 (95%) 0.12
CART or drainage (%) 84/170 (49%) 47/90 (52%) 15/37 (41%) 0.37
Denver shunt 6 (4%) 1 (1%) 3 (8%) 0.04
Laboratory data
Albumin (g/dL) 2.4 (1.5–4.2) 2.4 (1.6–3.6) 2.6 (1.7–4.2) 0.03
Total bilirubin (mg/dL) 1.9 (0.3–52.4) 2.2 (0.3–52.4) 2.0 (0.4–21.7) < 0.01
Aspartate aminotransferase (U/L) 48 (10–551) 52 (12–551) 42 (13–171) 0.06
Alanine aminotransferase (U/L) 28 (3–381) 29 (3–381) 29 (7–144) 0.53
γ-Glutamyl transpeptidase (U/L) 49 (9–269) 52 (9–269) 48 (9–229) 0.28
Platelet count (×104/μL) 8.8 (1.5–62.7) 8.8 (2.1–62.7) 7.6 (1.5–23.9) 0.10
Prothrombin time (PT%) 55.6 (16.3–90.3) 52.5 (16.3–89.0) 54.5 (19.5–90.3) 0.22
PT/INR 1.31 (0.98–3.17) 1.33 (1.04–3.17) 1.32 (0.98–2.84) 0.36
Ammonia (μg/dL) 66 (16–269) 60 (24–212) 85 (25–269) 0.11
α-fetoprotein (ng/mL) 4 (1–142,010) 4 (1–142,010) 4 (1–210) 0.13
Des-gamma-carboxy (mAU/mL) 68 (3–357,790) 73 (5–357,790) 27 (3–4994) 0.26
Blood urea nitrogen (mg/dL) 20.9 (5.5–125.3) 22.5 (5.8–64.3) 23.2 (6.0–63.3) 0.86
Creatinine (mg/dL) 0.99 (0.20–3.30) 1.00 (0.20–2.87) 1.04 (0.44–3.30) 0.28
eGFR (mL/min/1.73 m2) 53.9 (14.9–250.6) 53.1 (14.9–250.6) 49.5 (16.8–107.2) 0.06
Serum sodium (mEq/L) 136 (118–145) 135 (118–143) 137 (122–145) 0.01
Modified Child-Pugh (CP) score 11 (6–14) 11 (8–14) 11 (8–13) 0.05
MELD score 12 (1–37) 14 (1–37) 12 (2–29) 0.53
n number of patients, BW body weight, HCV hepatitis C virus, HBV hepatitis B virus, ALD alcoholic liver disease, NAFLD non-alcoholic fatty liver disease, PBC primary
biliary cholangitis, CART cell-free and concentrated ascites reinfusion therapy, eGFR estimated glomerular filtration rate, INR international normalized ratio, MELD
model for end-stage liver disease. Data are represented as the median (range)
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total bilirubin (p < 0.01) was significantly lower in pa-
tients who continued treatment. Although the modified
CP score tended to be low (mean value 11 [range: 8–13],
p = 0.05) in patients who continued treatment, the eGFR
was slightly reduced (49.5 [16.8–107.2] mL/min/1.73 m2
[p = 0.07]) in that group.
Changes in chemical parameters from baseline, and
analyses of factors predictive of continued long-term
tolvaptan treatment
To investigate whether long-term tolvaptan treatment
may improve liver and renal function, patients who were
treated for ≥1 year were assessed (n = 37, Table 3). Serum
Fig. 2 Distribution of diuretic use before tolvaptan treatment. The majority of cirrhotic patients with ascites who started tolvaptan treatment
were taking 0–50mg/day of spironolactone and 20–40mg/day of furosemide
Table 2 Patients who stopped tolvaptan treatment due to improved ascites
Age
(years old)
Sex Etiology of liver disease Tolvaptan
treatment (days)
Requirement for
restarting of
tolvaptan
Furosemide
(mg/day)
Spironolactone
(mg/day)
Modified
CP score
Event
60s Male Alcoholic liver disease 126 80 400 11 Discontinued
drinking
40s Male Hepatitis C virus-related liver
disease+ alcoholic liver
disease
1226 Yes 20 25 13 Discontinued
drinking
40s Male Alcoholic liver disease 49 Yes 20 100 12 Discontinued
drinking
70s Male Primary sclerosing cholangitis 335 160 100 11 Decreased
protein urea
60s Male Hepatitis B virus-related liver
disease
249 Yes 20 25 10 Treatment with
nucleic acid analog
80s Female Hepatitis C virus-related liver
disease
187 20 50 8 Disappearance
of portal vein
thrombosis
70s Male Alcoholic liver disease 293 20 25 10 Discontinued
drinking
60s Male Alcoholic liver disease+MTX
associated liver disease
186 10 25 11 Discontinued MTX
60s Female Alcoholic liver disease 139 10 25 12 Discontinued
drinking
CP Child-Pugh, MTX methotrexate
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Fig. 3 Distribution of tolvaptan treatment period. Overall, of the patients who discontinued tolvaptan treatment, 62 discontinued within 3
months, 30 in 3–6 months, and 31 in 6 months to 1 year. Only 37 patients were treated for ≥1 year. The median treatment period was 132 days
Table 3 Changes in laboratory data from baseline, and diuretic use after 1 year of tolvaptan treatment
(n = 37) Pretreatment Post-treatment p-value
Diuretic
Furosemide dose (mg/day) 20 (0–80) 20 (0–80) 0.28
Spironolactone dose (mg/day) 50 (0–150) 37.5 (0–150) 0.50
Laboratory data
Albumin (g/dL) 2.6 (1.7–4.2) 3.1 (1.5–4.4) < 0.01
Total bilirubin (mg/dL) 2.0 (0.4–21.7) 1.5 (0.3–8.2) 0.01
Aspartate aminotransferase (U/L) 42 (13–171) 34 (15–701) 0.09
Alanine aminotransferase (U/L) 29 (7–144) 20 (9–255) 0.14
γ-Glutamyl transpeptidase (U/L) 48 (9–229) 40 (12–285) 0.52
Platelet count (×104/μL) 7.6 (1.5–23.9) 7.7 (1.6–23.6) 0.64
Hematocrit (%) 28.6 (24.2–37.3) 32.0 (18.8–40.7) 0.06
Prothrombin time (PT%) 54.5 (19.5–90.3) 60.4 (19.4–89.4) 0.09
PT/INR 1.32 (0.98–2.84) 1.26 (1.01–2.70) 0.02
Ammonia (μg/dL) 85 (25–269) 67 (12–212) < 0.01
α-fetoprotein (ng/mL) 4 (1–210) 3 (1–17,734) 0.79
Des-gamma-carboxy (mAU/mL) 27 (3–4994) 27 (8–40,510) 0.53
Blood urea nitrogen (mg/dL) 23.2 (6.0–63.3) 25.4 (6.0–75.2) 0.99
Creatinine (mg/dL) 1.04 (0.44–3.30) 1.16 (0.50–2.48) 0.09
eGFR (mL/min/1.73 m2) 49.5 (16.8–107.2) 42.9 (15.3–136.3) 0.42
Serum sodium (mEq/L) 137 (122–145) 138 (123–144) 0.63
Modified Child-Pugh (CP) score 11 (8–13) 10 (6–13) < 0.01
MELD score 12 (2–29) 12 (3–22) 0.13
INR international normalized ratio, eGFR estimated glomerular filtration rate, n number of patients, MELD model for end-stage liver disease. Data are represented
as the median (range)
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levels of albumin were significantly increased (p <
0.01, Fig. 4a), whereas levels of total bilirubin (p =
0.06, Fig. 4b) and ammonia (p < 0.01, Fig. 4f ), and
the PT/INR (p = 0.02, Fig. 4d) were significantly re-
duced after 1 year of tolvaptan treatment. Renal
function was not affected (Fig. 4e). The modified CP
score improved significantly (p < 0.01, Fig. 4g) and
the MELD score was also reduced, but not signifi-
cantly (p = 0.13, Fig. 4h).
To identify predictive factors associated with contin-
ued administration of tolvaptan, multivariate logistic
regression analyses were used to assess changes in body
weight, gastroesophageal varices, HCC, hepatic enceph-
alopathy, eGFR, and levels of albumin, total bilirubin, as-
partate aminotransferase, and sodium (Table 4). Changes
in body weight and albumin levels were identified as
predictive factors (odds ratio [OR]: 1.320, 95% confi-
dence interval [CI]: 1.083–1.608, p = 0.006 and OR:
4.280, 95% CI: 1.136–16.127, p = 0.032, respectively).
In addition, eGFR was weakly associated with contin-
ued administration (OR: 0.978, 95% CI: 0.958–0.999,
p = 0.045).
Fig. 4 Changes in biochemical parameters in blood after 1 year of tolvaptan. a) Serum levels of albumin, b) total bilirubin, c) PT%, d) PT/INR, e)
creatinine, f) ammonia, g) the modified CP score, and h) MELD score. Albumin levels were significantly increased (a, p < 0.01), whereas total
bilirubin (b, p = 0.06), PT/INR (d, p = 0.02), and ammonia (f, p < 0.01) were reduced after 1 year of tolvaptan treatment. The modified CP score was
significantly improved (g, p < 0.01). The MELD score was also reduced, however, it not significantly (h, p = 0.13). PT, prothrombin time; INR,
international normalized ratio; CP, Child- Pugh; MELD, model for end-stage liver disease
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Discussion
We demonstrated that tolvaptan treatment for ≥1 year
significantly increased albumin levels and decreased the
PT/INR and ammonia levels. Factors associated with
continued administration included body weight reduc-
tion after 1 week and better liver function.
In the current study, patients who required liver trans-
plantation were included. Therefore, it was difficult to
analyze long-term tolvaptan treatment, because the
modified CP score had already attained 11 (range: 6–14).
In this condition, 37 cases (22%) with a modified CP
score of 11 (8–13) were observed for ≥1 year. Serum
levels of albumin were significantly higher in continu-
ously treated cases. While hematocrit values were
slightly increased by improving excess water, total biliru-
bin and ammonia levels were decreased. Therefore, the
increase in albumin level was thought to be due to im-
proved condition. Although the MELD score did not
differ significantly between the groups, the modified CP
score improved significantly in the group that continued
treatment (p < 0.01). We speculated that patients with im-
proved ascites had increased appetite and nutritional con-
dition, resulting in increased protein production ability.
Long-term administration of tolvaptan resulted in no
significant decrease in renal function. We previously re-
ported that liver transplant recipients maintained their
renal function after 1 year of transplantation [17]. Even
in chronic kidney disease, tolvaptan reduces the risk for
medium-term worsening renal function [18], because
tolvaptan is an aquaretic agent that removes excess
water without electrolyte excretion. Therefore, renal
functional loss was not exacerbated [19]. Furosemide
greatly increases urination, independent of the intravas-
cular volume, reducing renal function.
Regarding predictors associated with long-term treat-
ment, changes in body weight were significantly greater
in continued cases. Lower complication rates of esopha-
geal varices, total bilirubin levels, and higher serum
levels of albumin and sodium were predictive factors for
long-term treatment. Portal vein pressure is associated
with tolvaptan response [20]. A hepatic venous pressure
gradient (HVPG) of 190 mmH2O or less results in a
body weight reduction of 2 kg in a week. It has been sug-
gested that ascites accumulation is caused by not only
by low albumin levels but also portal hypertension.
Multiple logistic regression analyses showed that
changes in body weight reduction (OR: 1.320, 95% CI:
1.083–1.608, p = 0.006) and albumin levels (OR: 4.280,
95% CI: 1.136–16.127, p = 0.032) were predictive factors
for continued treatment. In addition to the baseline abil-
ity of the liver, tolvaptan response was important for
continued administration. Recently, response to tolvap-
tan was defined as a 1.5 kg/week reduction and this
value was expected to be an indicator of symptomatic
improvement [21]. Body weight reduction may also be
used as a predictor of long-term outcome.
By contrast, few reports have discussed the stopping of
tolvaptan treatment because liver cirrhosis is irreversible
and almost all patients fail to discontinue treatment. We
attempted to stop treatment by improving ascites in nine
patients (one patient stopped after ≥1 year treatment);
however, three patients relapsed and required retreat-
ment. These patients stopped consuming alcohol, ceased
methotrexate use, and underwent nucleic acid analog
treatment for HBV. These factors may have been associ-
ated with improved ascites, leading to functional im-
provement of the liver, even if the liver was in a cirrhotic
state. In particular, patients with ALD might have a
chance to recover if they stop drinking. The number of
patients who successfully completed tolvaptan treatment
was limited; therefore, the predictive factors were not
determined. However, cases with temporarily compro-
mised liver function and those initially engaging in treat-
ment may wish to discontinue the drug.
A limitation of this study was that it was a
single-center observational retrospective study. We
could not compare patients with and without tolvaptan
therapy; therefore, the direct effects of tolvaptan on al-
bumin levels were not determined. Further analyses to
determine the outcomes of long-term tolvaptan treat-
ment are required.
Conclusions
In conclusion, long-term treatment with tolvaptan in-
creased serum levels of albumin and decreased ammonia
levels after 1 year of treatment. Body weight reduction
after 1 week was associated with a favorable outcome of
tolvaptan therapy. Among patients who require radical
treatment for cirrhosis and still require ascites treat-
ment, tolvaptan administration should be maintained.
Table 4 Predictive factors for continued administration of tolvaptan for 1 year
Odds ratio 95% confidence interval p-value
Change in BW after 1 week (kg) 1.320 1.083–1.608 0.006
Albumin (g/dL) 4.280 1.136–16.127 0.032
eGFR (mL/min/1.73 m2) 0.978 0.958–0.999 0.045
Changes in body weight (BW), complications including gastroesophageal varices, hepatocellular carcinoma, and hepatic encephalopathy, and lab values including
estimated glomerular filtration rate (eGFR) and serum levels of albumin, total bilirubin, aspartate aminotransferase, and sodium were assessed using multivariate
logistic regression analyses
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